纵横研报
Tag

#oncology

03Reports
JAZZ.US logo
·制药 ·内部研究

Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act

Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.

JAZZ.US Jazz Pharmaceuticals plc #Zanidatamab#Ziihera#Xywav#Rare Disease#Oncology#Specialty Pharma
Hold
·制药 ·内部研究

BeOne Medicines: A Real Oncology Winner, Already Priced For More

BeOne Medicines, formerly BeiGene, is a global oncology biopharma whose economics now turn on one drug, BRUKINSA, the BTK inhibitor that outsold AstraZeneca's Calquence and AbbVie's Imbruvica in 2025 with $3.93 billion of revenue as the company crossed into sustained GAAP profitability. Full-year 2025 revenue reached $5.34 billion with $1.13 billion of operating cash flow, and first-quarter 2026 extended the trend with an 89% gross margin and raised full-year guidance, even as BRUKINSA still supplies roughly three-quarters of product revenue. Rating Hold: commercial execution and BTK leadership are real and durable, but at $303.96 the stock already prices continued BRUKINSA strength and a successful platform broadening that remains unproven, leaving no meaningful margin of safety.

ONC.US BeOne Medicines Ltd. #BRUKINSA#BTK Inhibitor#Oncology#Biopharma Turnaround#China-to-Global Biotech#TEVIMBRA
Hold
GSK.US logo
·制药 ·内部研究

GSK plc: Rebuilt Biopharma, Racing the Patent Cliff

GSK plc is a UK biopharma rebuilt around vaccines and specialty medicines after the 2022 Haleon demerger, with 2025 sales of £32.7bn anchored by Shingrix and the ViiV HIV franchise. Specialty medicines now drive growth (£13.5bn, +14% CER in Q1 2026) and core operating profit rose 11% to £9.8bn, yet the whole story hinges on replacing the dolutegravir HIV cliff in 2028–2030 before it arrives. Rating Hold: a genuinely higher-quality franchise at roughly 11.6x core earnings, but the price already assumes much of the patent-cliff bridge, leaving little margin of safety.

GSK.US GSK plc #pharmaceuticals#vaccines#HIV#Shingrix#oncology#patent cliff#dividend value
Hold